Pfizer third-quarter profit beats estimates, oncology drugs shine

By Ransdell Pierson (Reuters) - Pfizer Inc reported better-than-expected third-quarter earnings on Tuesday, helped by cuts in costs and growing sales of cancer medicines approved over the past two years. The largest U.S. drugmaker, whose shares rose 1.7 percent, earned $2.59 billion, or 39 cents per share. That compared with $3.21 billion, or 43 cents per share, in last year's quarter. Excluding special charges of $572 million related to restructurings, asset writedowns and other costs, Pfizer earned 58 cents per share. ...

via Health News Headlines - Yahoo! News Read More Here..